MR Imaging-Guided Vascular Procedures Using CO2 as a Contrast Agent von Wacker, Frank K, Maes, Robbert M, Jesberger, Jack A, Nour, Sherif G, Duerk, Jeffrey L, Lewin, Jonathan S

Volltext

A Novel Double-Contrast Technique to Facilitate MRI-Guided Vascular Interventions: Combined Use of a Blood-Pool Agent and Carbon Dioxide von Maes, Robbert M., Wacker, Frank K., Jesberger, Jack A., Duerk, Jeffrey L., Lewin, Jonathan S.

Volltext

MR Imaging–Guided Vascular Procedures Using CO 2 as a Contrast Agent von Wacker, Frank K., Maes, Robbert M., Jesberger, Jack A., Nour, Sherif G., Duerk, Jeffrey L., Lewin, Jonathan S.

Volltext

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 von Dowlati, Afshin, Robertson, Kelly, Radivoyevitch, Tomas, Waas, John, Ziats, Nicholas P, Hartman, Paul, Abdul-Karim, Fadi W, Wasman, Jay K, Jesberger, Jack, Lewin, Jonathan, McCrae, Keith, Ivy, Percy, Remick, Scot C

Volltext

Abstract 5297: Dual-modality imaging of hepatocellular carcinoma von Corn, David, Jesberger, Jack, Kolthammer, Jeffrey, Flask, Christopher, Lee, Zhenghong

Volltext

Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging von Ye, Zhen, Wu, Xueming, Tan, Mingqian, Jesberger, Jack, Grisworld, Mark, Lu, Zheng-Rong

Volltext

Differences in Brain Activation during a Novel fMRI task in Prenatally Cocaine-Exposed Adolescents von Minnes, Sonia, Tkach, Jean, Singer, Lynn, Weishampel, Paul, Jesberger, Jack, Stokes, Matthew

Volltext

5HTTLPR predicts left fusiform gyrus activation to positive emotional stimuli von Demaree, Heath A, Pu, Jie, Jesberger, Jack, Feeny, Norah, Jeng, Linda, Everhart, D. Erik, Duerk, Jeff, Tkach, Jean

Volltext

Original contribution: 5HTTLPR predicts left fusiform gyrus activation to positive emotional stimuli von Demaree, Heath A, Pu, Jie, Jesberger, Jack, Feeny, Norah, Jeng, Linda, Everhart, D Erik, Duerk, Jeff, Tkach, Jean

Volltext

Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Commentary von DOWLATI, Afshin, ROBERTSON, Kelly, MCCRAE, Keith, IVY, Percy, REMICK, Scot C, EMMENEGGER, Urban, KERBEL, Robert S, RADIVOYEVITCH, Tomas, WAAS, John, ZIATS, Nicholas P, HARTMAN, Paul, ABDUL-KARIM, Fadi W, WASMAN, Jay K, JESBERGER, Jack, LEWIN, Jonathan

Volltext